| Christopher Martin Coleman, MD | |
|
1460 Ne Medical Center Dr, Bend, OR 97701-6061 | |
| (541) 382-6633 | |
| (541) 382-2719 |
| Full Name | Christopher Martin Coleman |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 13 Years |
| Location | 1460 Ne Medical Center Dr, Bend, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952691800 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD195140 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Charles Medical Center - Bend | Bend, OR | Hospital |
| Wallowa Memorial Hospital | Enterprise, OR | Hospital |
| St Charles Prineville | Prineville, OR | Hospital |
| Blue Mountain Hospital | John day, OR | Hospital |
| Harney District Hospital | Burns, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Morrow County Health District | 2365359296 | 43 |
| Central Oregon Magnetic Resonance Imaging Llc | 8224058003 | 27 |
| Central Oregon Radiology Assoc Pc | 9335132091 | 35 |
| Cascade Medical Imaging Llc | 9537140108 | 29 |
News Archive
VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.
The long-term effects of botulinum toxin type A (Botox) in patients with severe movement disorders confirm the safety of the toxin's use in controlled dosages, according to a recent study at Baylor College of Medicine in Houston.
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease.
Magellan Health Services, Inc. today reported financial results for the third quarter of 2010, as summarized below, and increased guidance for the full year. For the quarter ended September 30, 2010, the Company reported net revenue of $750.3 million, segment profit of $90.1 million, and net income of $44.8 million or $1.31 per diluted common share.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance."
› Verified 1 days ago
| Entity Name | Morrow County Health District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770514481 PECOS PAC ID: 2365359296 Enrollment ID: O20040226001024 |
News Archive
VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.
The long-term effects of botulinum toxin type A (Botox) in patients with severe movement disorders confirm the safety of the toxin's use in controlled dosages, according to a recent study at Baylor College of Medicine in Houston.
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease.
Magellan Health Services, Inc. today reported financial results for the third quarter of 2010, as summarized below, and increased guidance for the full year. For the quarter ended September 30, 2010, the Company reported net revenue of $750.3 million, segment profit of $90.1 million, and net income of $44.8 million or $1.31 per diluted common share.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance."
› Verified 1 days ago
| Entity Name | Central Oregon Radiology Assoc Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477590081 PECOS PAC ID: 9335132091 Enrollment ID: O20040407000799 |
News Archive
VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.
The long-term effects of botulinum toxin type A (Botox) in patients with severe movement disorders confirm the safety of the toxin's use in controlled dosages, according to a recent study at Baylor College of Medicine in Houston.
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease.
Magellan Health Services, Inc. today reported financial results for the third quarter of 2010, as summarized below, and increased guidance for the full year. For the quarter ended September 30, 2010, the Company reported net revenue of $750.3 million, segment profit of $90.1 million, and net income of $44.8 million or $1.31 per diluted common share.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance."
› Verified 1 days ago
| Entity Name | Lake Health District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376698522 PECOS PAC ID: 4284629221 Enrollment ID: O20040419000549 |
News Archive
VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.
The long-term effects of botulinum toxin type A (Botox) in patients with severe movement disorders confirm the safety of the toxin's use in controlled dosages, according to a recent study at Baylor College of Medicine in Houston.
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease.
Magellan Health Services, Inc. today reported financial results for the third quarter of 2010, as summarized below, and increased guidance for the full year. For the quarter ended September 30, 2010, the Company reported net revenue of $750.3 million, segment profit of $90.1 million, and net income of $44.8 million or $1.31 per diluted common share.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance."
› Verified 1 days ago
| Entity Name | Morrow County Health District |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1376572099 PECOS PAC ID: 2365359296 Enrollment ID: O20061104000545 |
News Archive
VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.
The long-term effects of botulinum toxin type A (Botox) in patients with severe movement disorders confirm the safety of the toxin's use in controlled dosages, according to a recent study at Baylor College of Medicine in Houston.
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease.
Magellan Health Services, Inc. today reported financial results for the third quarter of 2010, as summarized below, and increased guidance for the full year. For the quarter ended September 30, 2010, the Company reported net revenue of $750.3 million, segment profit of $90.1 million, and net income of $44.8 million or $1.31 per diluted common share.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance."
› Verified 1 days ago
| Entity Name | Bend Memorial Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699827477 PECOS PAC ID: 7214936533 Enrollment ID: O20061215000022 |
News Archive
VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.
The long-term effects of botulinum toxin type A (Botox) in patients with severe movement disorders confirm the safety of the toxin's use in controlled dosages, according to a recent study at Baylor College of Medicine in Houston.
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease.
Magellan Health Services, Inc. today reported financial results for the third quarter of 2010, as summarized below, and increased guidance for the full year. For the quarter ended September 30, 2010, the Company reported net revenue of $750.3 million, segment profit of $90.1 million, and net income of $44.8 million or $1.31 per diluted common share.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance."
› Verified 1 days ago
| Entity Name | Cascade Medical Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932621588 PECOS PAC ID: 9537140108 Enrollment ID: O20171009003041 |
News Archive
VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.
The long-term effects of botulinum toxin type A (Botox) in patients with severe movement disorders confirm the safety of the toxin's use in controlled dosages, according to a recent study at Baylor College of Medicine in Houston.
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease.
Magellan Health Services, Inc. today reported financial results for the third quarter of 2010, as summarized below, and increased guidance for the full year. For the quarter ended September 30, 2010, the Company reported net revenue of $750.3 million, segment profit of $90.1 million, and net income of $44.8 million or $1.31 per diluted common share.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance."
› Verified 1 days ago
| Entity Name | Central Oregon Magnetic Resonance Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114972155 PECOS PAC ID: 8224058003 Enrollment ID: O20171018001990 |
News Archive
VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.
The long-term effects of botulinum toxin type A (Botox) in patients with severe movement disorders confirm the safety of the toxin's use in controlled dosages, according to a recent study at Baylor College of Medicine in Houston.
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease.
Magellan Health Services, Inc. today reported financial results for the third quarter of 2010, as summarized below, and increased guidance for the full year. For the quarter ended September 30, 2010, the Company reported net revenue of $750.3 million, segment profit of $90.1 million, and net income of $44.8 million or $1.31 per diluted common share.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance."
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Martin Coleman, MD 1460 Ne Medical Center Dr, Bend, OR 97701-6061 Ph: (541) 382-6633 | Christopher Martin Coleman, MD 1460 Ne Medical Center Dr, Bend, OR 97701-6061 Ph: (541) 382-6633 |
News Archive
VIB scientists associated to the UGent have developed a mouse model that can advance the research on iPS cells to the next step.
The long-term effects of botulinum toxin type A (Botox) in patients with severe movement disorders confirm the safety of the toxin's use in controlled dosages, according to a recent study at Baylor College of Medicine in Houston.
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease.
Magellan Health Services, Inc. today reported financial results for the third quarter of 2010, as summarized below, and increased guidance for the full year. For the quarter ended September 30, 2010, the Company reported net revenue of $750.3 million, segment profit of $90.1 million, and net income of $44.8 million or $1.31 per diluted common share.
Many patients who have genetic testing for Lynch syndrome, a hereditary predisposition to colon cancer, receive the inconclusive result "variants of uncertain clinical significance."
› Verified 1 days ago
Dr. Nicholas Song Boehling, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2500 Ne Neff Rd, Bend, OR 97701 Phone: 541-706-5800 Fax: 541-706-6341 | |
Dr. Casey George Curran, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1460 Ne Medical Center Dr, Bend, OR 97701 Phone: 541-382-6633 Fax: 541-382-2719 | |
Dr. Brant David Wommack, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1460 Ne Medical Ctr Dr, Bend, OR 97701 Phone: 541-382-6633 Fax: 541-382-2719 | |
Richard Rotondi, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 2052 Ne 4th St, Bend, OR 97701 Phone: 541-280-2789 | |
Dr. Jeremy James Logan, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1460 Ne Medical Center Dr, Bend, OR 97701 Phone: 541-382-6633 Fax: 541-383-4577 | |
Steven Dean Kjobech, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1460 Ne Medical Center Dr, Bend, OR 97701 Phone: 541-382-6633 Fax: 541-382-2719 | |
Dr. David Krieves, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 1460 Ne Medical Center Dr, Bend, OR 97701 Phone: 541-382-6633 Fax: 541-382-9327 |